Salarius Pharmaceuticals Crescita futura

Future criteri di controllo 0/6

Si prevede che gli utili di Salarius Pharmaceuticals diminuiranno a una percentuale pari a 56.1% all'anno. Si prevede che l'EPS diminuirà a una percentuale pari a 69.8% all'anno.

Informazioni chiave

-56.1%

Tasso di crescita degli utili

-69.8%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	42.4%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	09 Sep 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:FP10 - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	N/A	-23	N/A	N/A	1
12/31/2024	N/A	-22	N/A	N/A	1
6/30/2024	N/A	-6	-8	-8	N/A
3/31/2024	N/A	-9	-11	-11	N/A
12/31/2023	N/A	-13	-13	-13	N/A
9/30/2023	N/A	-18	-16	-16	N/A
6/30/2023	N/A	-30	-18	-18	N/A
3/31/2023	N/A	-31	-17	-17	N/A
12/31/2022	N/A	-32	-19	-18	N/A
9/30/2022	N/A	-29	-17	-16	N/A
6/30/2022	N/A	-19	-13	-11	N/A
3/31/2022	1	-17	-12	-11	N/A
12/31/2021	2	-13	-10	-10	N/A
9/30/2021	3	-11	-9	-9	N/A
6/30/2021	5	-9	-10	-10	N/A
3/31/2021	5	-8	-9	-9	N/A
12/31/2020	5	-8	-10	-10	N/A
9/30/2020	5	-7	-12	-12	N/A
6/30/2020	4	-8	-14	-14	N/A
3/31/2020	4	-7	-13	-13	N/A
12/31/2019	3	-7	-12	-12	N/A
9/30/2019	3	-6	-9	-9	N/A
6/30/2019	3	-4	2	2	N/A
3/31/2019	2	-3	3	3	N/A
12/31/2018	2	-2	4	4	N/A
9/30/2018	1	-2	3	3	N/A
12/31/2017	2	-2	N/A	-1	N/A
12/31/2016	3	-1	N/A	0	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che FP10 rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che FP10 rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che FP10 rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di FP10 cresceranno più rapidamente del mercato German.

Ricavi ad alta crescita: Si prevede che FP10 non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di FP10 è previsto essere elevato tra 3 anni

Salarius Pharmaceuticals Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

New 90-day high: €1.16

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

New 90-day high: €1.05

New 90-day high: €0.88

Third quarter 2020 earnings released: US$0.096 loss per share

Revenue beats expectations

New 90-day low: €0.66

New 90-day low: €0.67

New 90-day low - €0.79

New 90-day low - €0.83

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita